安进Amgen Inc. (AMGN) 2008年年度报告「NASDAQ」.pdf

1、Amgen 2008 Annual Report and Financial SummaryProductsAmgen discovers,develops,manufactures and delivers innovative human therapeutics.A biotechnology pioneer since 1980,Amgen was one of the fi rst companies to realize the new sciences promise by bringing safe and effective medicines from the lab to

2、 the manufacturing plant to patients.Amgen therapeutics have changed the practice of medicine,helping millions of people around the world in the fi ght against cancer,kidney disease,rheumatoid arthritis and other serious illnesses,and so far,more than 15 million patients worldwide have been treated

3、with Amgen products.With a broad and deep pipeline of potential new medicines,Amgen remains committed to advancing science to dramatically improve peoples lives.About AmgenPioneering science delivers vital medicinesAranesp(darbepoetin alfa)Enbrel(etanercept)EPOGEN(Epoetin alfa)Neulasta(pegfi lgrasti

4、m)NEUPOGEN(Filgrastim)Nplate(romiplostim)Sensipar(cinacalcet)Vectibix(panitumumab)Total revenues($in millions)2008$15,003 2007 14,771 2006 14,2682005 12,4302004 10,55005060704082008$4.552007 4.292006 3.902005 3.202004 2.40“Adjusted”earnings per share(EPS)*(Diluted)0506070408Cash fl ow from operation

5、s($in millions)2008$5,988 2007 5,4012006 5,3892005 4,9112004 3,6970506070408“Adjusted”research and development(R&D)expenses*($in millions)2008$2,910 2007 3,0642006 3,1912005 2,3022004 1,9960506070408*“Adjusted”EPS and“adjusted”R&D expenses are non-GAAP fi nancial measures.See page 8 for reconciliati

6、ons of these non-GAAP fi nancial measures to U.S.Generally Accepted Accounting Principles(GAAP).Amgens most important news in 2008 was our progress in advancing our pipeline.2008 was a good year for Amgen,its stockholders and the patients we serve.Amgens most important news in 2008 was our progress